SCHEMBL7052909

SCHEMBL7052909

CCOC(=O)c1ccc(N2CCCCC2N)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 3/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 6/20 0.40
TSHR P16473 4/20 0.40
HTT P42858 1/20 0.40
NPC1 O15118 1/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.39
PKM P14618 2/20 0.39
HPGD P15428 2/20 0.39
ALOX15 P16050 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LMNA P02545 3/20 0.38
JMJD6 Q6NYC1 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7467830 0.89 MAPT (0.44) RAB9AKDM4EMAPTALDH1A1TSHR
SCHEMBL7463261 0.87 CASP3 (0.42) RAB9AKDM4EMAPTALDH1A1TSHR
SCHEMBL7468705 0.87 KDM4E (0.41) RAB9AKDM4EMAPTALDH1A1TSHR
SCHEMBL7051580 0.82 HPGD (0.50) RAB9AMAPTALDH1A1HTTNPC1
SCHEMBL4508521 0.81 MAPT (0.52) RAB9AKDM4EMAPTALDH1A1TSHR
SCHEMBL7050641 0.80 OPRK1 (0.42) RAB9AMAPTALDH1A1TSHRHTT
SCHEMBL7052910 0.80 PRKD3 (0.47) RAB9AKDM4EMAPTALDH1A1TSHR
SCHEMBL382515 0.78 HTT (0.51) RAB9AKDM4EMAPTALDH1A1TSHR
SCHEMBL28044539 0.77 MYC (0.42) RAB9AKDM4EMAPTALDH1A1NPC1
SCHEMBL31542266 0.75 MAPT (0.46) RAB9AKDM4EMAPTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030040531-A1 Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist MEIJI SEIKA KAISHA, LTD. (JP) 2003-02-27 US disclosed
EP-1250935-A1 REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST MEIJI SEIKA KAISHA LTD. (JP) 2002-10-23 EP disclosed
EP-1227083-A1 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS MEIJI SEIKA KAISHA LTD. (JP) 2002-07-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040531-A1 Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist ITGB3, ITGAV, ITGB1 RAB9A 1234/4885KDM4E 4216/4885MAPT 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.